Recent advances in lowering CV risk with antidiabetic agents

3' education - Feb. 12, 2016 - Boston, MA, USA - Prof Stephen Wiviott

Video navigation menu

What can be done about the increasing prevalance of diabetes and associated CV disease? 0:15
Assessing CV benefit of diabetes agents in large CV outcomes trials 2:41
Targeting the SGLT2 transporter to lower blood glucose exerts various effects 3:24
Are the EMPA-REG OUTCOMES results reproducible? 7:27
Where are we now with anti-diabetic treatment in relation to lowering CV risk? 8:36

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.